122 related articles for article (PubMed ID: 37753656)
41. Assessing variation in the costs of care among patients awaiting liver transplantation.
Axelrod DA; Dzebisashvili N; Lentine K; Segev DL; Dickson R; Tuttle-Newhall E; Freeman R; Schnitzler M
Am J Transplant; 2014 Jan; 14(1):70-8. PubMed ID: 24165015
[TBL] [Abstract][Full Text] [Related]
42. Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points.
Hart A; Schladt DP; Zeglin J; Pyke J; Kim WR; Lake JR; Roberts JP; Hirose R; Mulligan DC; Kasiske BL; Snyder JJ; Israni AK
Transplantation; 2016 Oct; 100(10):2153-9. PubMed ID: 27490411
[TBL] [Abstract][Full Text] [Related]
43. MELD is MELD is MELD? Transplant center-level variation in waitlist mortality for candidates with the same biological MELD.
Ishaque T; Kernodle AB; Motter JD; Jackson KR; Chiang TP; Getsin S; Boyarsky BJ; Garonzik-Wang J; Gentry SE; Segev DL; Massie AB
Am J Transplant; 2021 Oct; 21(10):3305-3311. PubMed ID: 33870635
[TBL] [Abstract][Full Text] [Related]
44. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
[TBL] [Abstract][Full Text] [Related]
45. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
[TBL] [Abstract][Full Text] [Related]
46. Do Social Determinants Define "Too Sick" to Transplant in Patients With End-stage Liver Disease?
Bababekov YJ; Hung YC; Chang DC; Rickert CG; Adler JT; Bethea E; Pomfret EA; Pomposelli JJ; Yeh H
Transplantation; 2020 Feb; 104(2):280-284. PubMed ID: 31335769
[TBL] [Abstract][Full Text] [Related]
47. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
Nobel YR; Goldberg DS
Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
[TBL] [Abstract][Full Text] [Related]
48. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
[TBL] [Abstract][Full Text] [Related]
49. Implementation of a National Liver Review Board for exception requests in the United States: A 2-year monitoring report.
Kwong AJ; Foutz J; Cafarella M; Biggins SW; Shah ND; Eason J; Perito ER; Pomposelli J; Trotter J
Liver Transpl; 2024 Apr; 30(4):367-375. PubMed ID: 37639285
[TBL] [Abstract][Full Text] [Related]
50. Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients.
Stepanova M; Kabbara K; Mohess D; Verma M; Roche-Green A; AlQahtani S; Ong J; Burra P; Younossi ZM
Hepatol Commun; 2022 Jul; 6(7):1506-1515. PubMed ID: 35224886
[TBL] [Abstract][Full Text] [Related]
51. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
[TBL] [Abstract][Full Text] [Related]
52. Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis.
Vitale A; Saracino E; D'Amico FE; Grigoletto F; Burra P; Angeli P; Boccagni P; Brolese A; Zanus G; Neri D; Gringeri E; D'Amico F; Valmasoni M; Carraro A; Gambato M; Feltracco P; Romano A; Buggio M; D'Amico DF; Cillo U
Transplant Proc; 2009 May; 41(4):1092-5. PubMed ID: 19460489
[TBL] [Abstract][Full Text] [Related]
53. Changing opportunities for liver transplant for patients with hepatocellular carcinoma.
Zendel A; Watkins R; Moon AM; Gerber DA; Barritt AS; Desai CS
Clin Transplant; 2022 May; 36(5):e14609. PubMed ID: 35137467
[TBL] [Abstract][Full Text] [Related]
54. Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator.
Díaz LA; Norero B; Lara B; Robles C; Elgueta S; Humeres R; Poniachik J; Silva G; Wolff R; Innocenti F; Rojas JL; Zapata R; Hunter B; Álvarez S; Cancino A; Ibarra J; Rius M; González S; Calabrán L; Pérez RM
Ann Hepatol; 2019; 18(2):325-330. PubMed ID: 31010794
[TBL] [Abstract][Full Text] [Related]
55. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
[TBL] [Abstract][Full Text] [Related]
56. Shorter Height Is Associated With Lower Probability of Liver Transplantation in Patients With Hepatocellular Carcinoma.
Lee E; Sarkar M; Dodge J; Kohi M; Mehta N
Transplantation; 2020 May; 104(5):988-995. PubMed ID: 31577670
[TBL] [Abstract][Full Text] [Related]
57. Reassessing the survival benefit of deceased donor liver transplantation: retrospective cohort study.
Malamon JS; Kaplan B; Jackson WE; Saben JL; Schold JD; Pomfret EA; Pomposelli JJ
Int J Surg; 2023 Sep; 109(9):2714-2720. PubMed ID: 37226874
[TBL] [Abstract][Full Text] [Related]
58. Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions.
Umgelter A; Hapfelmeier A; Kopp W; van Rosmalen M; Rogiers X; Guba M;
Liver Transpl; 2017 Oct; 23(10):1256-1265. PubMed ID: 28650098
[TBL] [Abstract][Full Text] [Related]
59. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
Kwong AJ; Lai JC; Dodge JL; Roberts JP
Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
[TBL] [Abstract][Full Text] [Related]
60. Use of model for end-stage liver disease exceptions for donation after cardiac death graft recipients relisted for liver transplantation.
Maduka RC; Abt PL; Goldberg DS
Liver Transpl; 2015 Apr; 21(4):554-60. PubMed ID: 25597393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
